Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation

Treatment‐free remission (TFR) by tyrosine kinase inhibitors (TKI) discontinuation in patients with deep molecular response (DMR) is a paramount goal in the current chronic myeloid leukemia (CML) therapeutic strategy. The best DMR level by real‐time quantitative PCR (RT‐qPCR) for TKI discontinuation...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernardi, Simona, Malagola, Michele, Zanaglio, Camilla, Polverelli, Nicola, Dereli Eke, Elif, D’Adda, Mariella, Farina, Mirko, Bucelli, Cristina, Scaffidi, Luigi, Toffoletti, Eleonora, Deambrogi, Clara, Stagno, Fabio, Bergamaschi, Micaela, Franceschini, Luca, Abruzzese, Elisabetta, Divona, Maria Domenica, Gobbi, Marco, Di Raimondo, Francesco, Gaidano, Gianluca, Tiribelli, Mario, Bonifacio, Massimiliano, Cattaneo, Chiara, Iurlo, Alessandra, Russo, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536984/
https://www.ncbi.nlm.nih.gov/pubmed/30950237
http://dx.doi.org/10.1002/cam4.2087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536984/
https://www.ncbi.nlm.nih.gov/pubmed/30950237
http://dx.doi.org/10.1002/cam4.2087

Ejemplares similares